Although activating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum, which has a large excess of helical domain mutations. We investigated the phenotypic and signaling consequences of hotspot and UC-specific rare PIK3CA mutations in immortalized normal human urothelial cells (NHUC) and mouse fibroblasts (NIH3T3). Our results indicate that in NHUC, rare mutant forms and all three hotspot mutant forms of PIK3CA can activate the PI3K/AKT pathway. The relative frequency at which helical domain and kinase domain mutations are found in UC is related to their potency in inducing signaling downstream of AKT and to the phenotypic effects induced in this cell type (E545K4E542K4H1047R). Helical domain mutations E542K and E545K conferred a significant proliferative advantage at confluence and under conditions of nutrient depletion, and increased cellular resistance to anoikis. Both helical and kinase domain mutants induced increased NHUC cell motility and migration towards a chemoattractant, though no significant differences were found between the mutant forms. In NIH3T3 cells, the kinase domain mutant H1047R induced high levels of AKT activation, but helical domain mutants were significantly less potent and this was reflected in their relative abilities to confer anchorage-independent growth. Our findings indicate that the effects of mutant PIK3CA are both cell type-and mutation-specific. Helical domain mutations in PIK3CA may confer a selective advantage in the urothelium in vivo by overcoming normal contact-mediated inhibitory signals and allowing proliferation in nutrient-limiting conditions. Mutant forms of PIK3CA may also stimulate intraepithelial cell movement, which could contribute to spread of cells within the urothelium.
INTRODUCTION
Mutations in the class IA PI3K p110a and its associated regulatory subunit p85a are clearly implicated in human cancer.
1,2 Activating mutations in PIK3CA, encoding p110a, are found in many human cancers, including urothelial carcinoma (UC).
3 --8 PIK3CA mutations are found in bladder tumors of all grades and stages but are more common in those of low grade and stage. 7, 8 Most mutations in UC and other human cancers are the hotspot mutations E542K, E545K and H1047R, located in the helical and kinase domains. The mutation spectrum in bladder tumors differs significantly from other tumors, with an excess of E545K and E542K 7 --10 (Catalogue of Somatic Mutations in Cancer, www.sanger.ac.uk/genetics/CGP/ cosmic). The selective pressure for helical domain mutations in UC
is not yet understood.
Many other PIK3CA mutations have been identified at low frequency and some of these have gain of function and transforming activity. 11 --13 Mutations identified in UC include rare mutations found in other cancers (E545G, E545Q, G1007R, D1017H, M1043I and H1047L) and novel mutations (P124L, V136I Q643R and A1066V) 7, 8 (Platt et al., unpublished data) . Of these, E545G and M1043I have been functionally linked to increased PI3K lipid kinase activity, constitutive AKT activation and transformation of chick embryo fibroblasts and NIH3T3 cells. 11, 13 The activity of the other rare mutants has not been examined.
Most functional studies have focused on hotspot mutant forms of PIK3CA and have been performed in non-human cell lines or cancer cell types other than bladder. To date, no studies have examined effects in normal human epithelial cells. As UC has a specific mutation spectrum and several novel PIK3CA mutations, it is important to investigate their effects in urothelial cells. Here, we have examined the effects of hotspot and rare mutant PIK3CA mutant proteins in immortalized normal human urothelial cells (NHUC) and compared effects in immortal mouse fibroblasts (NIH3T3), that are commonly used to assess oncogenic human proteins. We show a correlation between the relative frequency of PIK3CA mutations in UC and the level of ligand independence, signaling activation and phenotypic consequences induced in NHUC, indicating a context-dependent basis for the observed mutation spectrum.
RESULTS
Cell context-dependent pathway activation by common and rare mutant forms of PIK3CA We generated retroviral vectors encoding wild-type (WT) PIK3CA, the three major hotspot variants (E542K, E545K and H1047R) and 7 rare variants previously identified in bladder tumors or cell lines. Stable pools of NHUC and NIH3T3 expressing these forms were generated. The cells were designated WT-NHUC/NIH3T3 and E542K-, E545K-, H1047R-, P124L-, V136I-, E545G-, Q643R-, D1017H-, M1043I-and A1066V-NHUC/NIH3T3. Expression was confirmed by western blotting (Supplementary Figure S1) . In NHUC, 7 days after retroviral transduction, PIK3CA protein levels were 7 --10-fold higher than endogenous levels and decreased to 2 --4-fold greater than endogenous levels by 15 days. WT and mutant PIK3CA NIH3T3 had consistent 4 --11-fold greater PIK3CA protein levels than controls (Supplementary Figure S1) .
To determine the effect of mutant PIK3CA expression on PI3K pathway signaling, cells were cultured in growth factor-depleted medium and pAKT (Ser473) levels examined (Figures 1a and b) . In NHUC, hotspot mutant forms and the helical domain mutant E545G had the greatest ability to induce AKT activation. Of these, E542K had least effect. All of the rare mutant forms showed some ability to activate AKT, with least phosphorylation in V136I-and Q643R-NHUC.
In contrast, in NIH3T3, the helical domain mutant forms induced only a minor increase in AKT phosphorylation. In these cells, H1047R had the greatest effect, with 14-fold greater pAKT levels compared with controls. E542K-, E545K-, P124L-and E545G-NIH3T3 had approximately 3-fold higher pAKT than controls. Thus, the rare mutant P124L had low potency, similar to helical domain hotspot mutants in this cell context, and V136I, Q643R, D1017H, M1043I and A1066V induced no significant increase in AKT phosphorylation. Overexpression of WT-PIK3CA did not significantly increase AKT phosphorylation in either cell type (Figures 1a and b) .
We then assessed the ability of the three hotspot mutant forms of PIK3CA to activate the PI3K pathway downstream of AKT in NHUC in growth factor-supplemented and -depleted conditions by analyzing pGSK3b, pFOXO3a, pFOXO1 and pS6 levels (Figure 1c ), read-outs that have been used previously to determine PI3K-dependent AKT signaling pathway activation. 14 In growth factor-depleted medium, mutant PIK3CA-NHUC had increased pGSK-3b levels (9.5 --11-fold greater than controls), pFOXO1 levels (6 --9.5-fold greater than controls) and pFOXO3a levels (15 --21-fold greater than controls), with E545K-NHUC having the highest levels ( Figure 1c and Supplementary Figure S2) . Although E542K-NHUC had lower levels of pAKT compared with cells expressing the other hotspot mutant forms, these cells showed high levels of GSK-3b, FOXO1 and FOXO3a phosphorylation. The highest FOXO1 and FOXO3a phosphorylation and inactivation was seen in cells expressing helical domain mutants. Overexpression of WT-PIK3CA did not induce potent phosphorylation of GSK-3b, FOXO1 or FOXO3a, although levels were 2.5 --5-fold greater than controls. All PIK3CA-expressing NHUC had increased pS6 levels under growth factor-depleted conditions ( Figure 1c and Supplementary Figure S2 ).
Together these results indicate that in normal human urothelial cells all three hotspot mutant forms of PIK3CA can potently activate the PI3K/AKT pathway, that rare mutant forms found previously in UC show activity in these cells, and that the relative frequency at which PIK3CA helical and kinase domain mutations are found in UC is related to the hierarchy of elevated signaling downstream of AKT (E545K4E542K4H1047R). In addition, a clear cell context-dependent difference between urothelial and rodent mesenchymal cells in the potency of activation of downstream signaling by the three hotspot mutants is apparent. Figure 1 . PI3K-AKT pathway activation in WT and mutant PIK3CA-NHUC and -NIH3T3. Immunoblots showing levels of pAKT (Ser473) in NHUC (a) and NIH3T3 (b) cultured in growth factor-depleted conditions. pAKT levels were normalized to total AKT. Bar charts show quantification of normalized pAKT relative to controls. (c) Immunoblot analysis of PI3K signaling in WT and mutant PIK3CA-NHUC and controls in growth factor-supplemented medium ( þ ) and growth factor-depleted medium (À). Blots were probed for pAKT (Ser473), pGSK3b (Ser9), pFOXO1 (Thr24), pFOXO3a (Thr32) and pS6 (Ser235/236). Phosphoprotein levels were normalized to total protein levels and quantified (Supplementary Figure S2) . Data are representative of triplicate experiments.
Phenotypic consequences of mutant PIK3CA expression are cell context-dependent Many NHUC expressing hotspot mutant PIK3CA exhibited a large, vacuolated and flattened morphology compared with controls (Supplementary Figure S3a) . Flow cytometry analysis confirmed an increase in median cell size (Supplementary Figures S3b and c) . Control cells showed a slightly positively skewed size distribution, and this was greatly enhanced in cells expressing hotspot mutant forms of PIK3CA, which had a significantly larger upper quartile size threshold. Expression of H1047R-PIK3CA had the greatest effect. WT-NHUC had similar morphology and cell size profile to controls. A large, vacuolated morphology is a common phenotypic marker of senescent cells. Staining for senescenceassociated beta-galactosidase (b-gal) activity indicated a greater proportion of positive staining in cells expressing hotspot mutant PIK3CA relative to controls (Supplementary Figure S4a) and this was mostly confined to large, flattened cells (Supplementary Figure S4b) . Overexpression of WT-PIK3CA increased the proportion of positively stained cells relative to controls, but to a lesser degree than the hotspot PIK3CA mutants (Supplementary Figure  S4a) . Expression of mutant PIK3CA in NIH3T3 did not induce any morphological change or change in cell size (data not shown).
Upregulation of p16 INK4A is implicated in oncogene-mediated senescence. As deletion of one allele of the CDKN2A locus is a predicted early event during bladder tumor development, we tested whether downregulation of p16 might abrogate the senescence-like effect induced by ectopic expression of mutant PIK3CA in NHUC. Indeed, the phenotype was markedly reduced in NHUC with stable knockdown of p16 expression (Supplementary Figure S5) .
The effects of expression of hotspot mutant PIK3CA on proliferation of NHUC and NIH3T3 were assessed. During exponential growth in growth factor-supplemented conditions, E545K-and H1047R-NHUC had reduced proliferation rates compared with controls, the latter showing the greatest inhibition ( Figure 2a ). This was associated with an increase in p16 expression, Figure 2 . Proliferative indices of WT and hotspot mutant PIK3CA-NHUC and -NIH3T3 in growth factor-supplemented medium ( þ GF) and growth factor-depleted medium (ÀGF). Fold increase in NHUC (a) and NIH3T3 (b) total cell numbers during exponential growth between days 1 and 7 in growth factor-supplemented conditions relative to controls. Fold increase of NHUC (c) and NIH3T3 (d) cell saturation densities, relative to controls. Fold increase in NHUC total cell numbers during exponential growth between days 1 and 7 (e) and cell saturation densities (f ) in growth factor-depleted conditions, relative to vector controls. * indicates statistically significant difference from controls according to ANOVA test (Po0.05). Values represent mean±s.e. Results are representative of triplicate experiments.
with the highest levels of p16 immunostaining in H1047R-NHUC (data not shown). WT-NHUC showed increased proliferation relative to controls. E542K-NHUC also had a proliferative advantage, though this was not statistically significant. In contrast, proliferation of NIH3T3 was stimulated by all hotspot mutants (H1047R4E542K4E545K) but not by WT-PIK3CA (Figure 2b ).
Saturation density of confluent monolayers of NHUC expressing hotspot mutant PIK3CA was also assessed. In growth factorsupplemented conditions, H1047R-NHUC reached the same cell saturation density as controls (Figure 2c ), but 4 days later than controls owing to their slower proliferation rate. WT-, E542K-and E545K-NHUC continued to proliferate at confluence and reached significantly higher saturation densities, with the greatest advantage conferred by E542K-PIK3CA. BrdU and p16 immunocytochemistry supported this finding, with WT-, E542K-, and E545K-NHUC having significantly greater numbers of BrdU positive and lower numbers of p16 positive cells compared with controls and H1047R-NHUC (Supplementary Figure S6) . Thus, expression of WT-, E542K-and E545K-PIK3CA conferred a growth advantage at confluence, and cell proliferation was not contact inhibited. In contrast, H1047R was the only mutant PIK3CA form that conferred increased saturation density in NIH3T3 (Figure 2d ).
Proliferation of NHUC was also measured under conditions of growth factor-depletion. Hotspot mutant PIK3CA-NHUC had a significant proliferative advantage over controls and WT-NHUC when cultured at low cell densities, with the greatest advantage in E545K-NHUC (Figure 2e ). BrdU and p16 immunocytochemistry confirmed that E542K-and E545K-NHUC had a growth advantage at high cell densities and that WT-NHUC also had an increased proportion of BrdU-stained cells (Supplementary Figure S6a) . Helical domain mutant PIK3CA-NHUC achieved the highest saturation densities in growth factor-depleted conditions, with the greatest effect seen in E545K-NHUC (Figure 2f ). H1047R-and WT-NHUC had similar saturation densities to controls.
Anchorage-independence of E545K-and H1047R-NHUC was tested in soft agar. Although mutant PIK3CA expression did not induce colony formation in NHUC, there was a significant increase in viability of single cells after 3 weeks, indicating resistance to anoikis. E545K-NHUC had the greatest number of viable cells (Figure 3a) . All mutant PIK3CA-NIH3T3 cells, apart from V136I-NIH3T3, formed small colonies (410 mm 2 ) and H1047R-NIH3T3 showed highest frequency of colonies 420 mm 2 ( Figures 3b --d) .
Taken together, these results indicate that in normal urothelial cells, helical domain mutations E542K and E545K confer a significant proliferative advantage at confluence and under conditions of nutrient depletion and confer higher resistance to anoikis. These effects are greater than those induced by H1047R, and this correlates with the frequency at which each mutation is found in UC (E545K4E542K4H1047R). The significant differences found in NIH3T3 indicate clear cell context-dependent effects.
Finally, the relative motility of WT and mutant PIK3CA-NHUC was compared using monolayer wound-healing assays. In growth factor-supplemented conditions, no differences were observed (data not shown). In growth factor-depleted conditions, E542K-, E545K-, H1047R-, E545G-, D1017H-and A1066V-NHUC closed the wounds within 9 h compared with 416 h for controls (Figure 4) . P124L-and M1043I-NHUC also showed increased motility with wounds healed between 9 and 16 h. These cells showed increased velocity and directional motility compared with controls ( Figure 4) . The motility of WT-, V136I-and Q643R-NHUC was not different from controls. Hotspot mutant PIK3CA-NHUC also had significantly greater cell migration towards a chemoattractant (growth factorsupplemented medium) than controls and WT-NHUC (Figure 4) . They also showed increased velocities of random cell motility in confluent monolayers in growth factor-depleted conditions (Supplementary Figure S7) . In these assays, no significant differences between cells expressing helical domain and kinase domain mutants were observed.
In silico analysis of the functional relevance of novel PIK3CA mutations within the PI3K heterodimer Our results indicated that several of the rare novel mutant forms of PIK3CA had functional significance in urothelial cells. We examined the crystal structure of PIK3CA 15 to assess their possible impact on the known function and interactions of the protein. P124L may affect the regulatory interaction of p85a with p110a. Pro124 is in close proximity to residues Glu76 and Glu78 of the p85-binding domain of p110a (within 5 Å) (Supplementary Figure S8) . The intervening residue, Ala77, lies on the turn of the loop and has a predicted hydrophobic interaction with Ala486 of the iSH2 domain of p85a. The mutant Leu124 sidechain has a predicted steric clash with Glu78, which may interfere with this. Q643R is predicted to affect interaction of the helical and C2 domains of p110a. Glu643 has close contact with C2 domain residues Ala399, Arg401 and Arg398 (within 4 Å) (Supplementary Figure S8) . The mutant Arg643 sidechain is in close proximity to Arg401 and Arg398. As they are all positively charged, the mutant residue is predicted to repulse these C2 domain residues. Steric repulsion is also predicted between Arg643 and Ala399. V136I appears unlikely to be functionally significant, as substitution of Ile is not predicted to alter interactions with neighboring residues (data not shown). The functional significance of A1066V could not be analyzed as the available crystal structure is truncated at amino acid 1050.
DISCUSSION
Activating mutations in PIK3CA are found in a wide variety of human cancers including 27% of UC. 7, 8 However, the ratio of kinase:helical domain mutations differs significantly according to cancer type. This ranges from 42 in endometrial cancer to 0.29 in bladder cancer, which is the lowest ratio recorded to date (COSMIC; data accessed June 2011). It is well recognized that non-invasive and invasive bladder cancer types are distinct disease entities with different molecular profiles. 16 There is a lower PIK3CA mutation frequency in invasive tumors, 7 but an excess of helical domain mutations is found in both groups (our unpublished data).
As the mechanism by which kinase and helical domain mutations activate PI3K is different, 17 it is likely that these ratios reflect cell context-related differences. Therefore, functional studies require evaluation in relevant cell types. In tissues such as the urothelium, where involvement of PIK3CA may be an early event in tumor development, the normal cell context seems most relevant. To date, all functional analyses of PIK3CA mutants in epithelial cells have been carried out in tumor cells or immortal cells that have been engineered to contain some of the molecular alterations required for transformation 18 or have acquired such alterations spontaneously, for example MCF-10A. 19 This is the first study to investigate the signaling and phenotypic consequences of mutant PIK3CA in normal epithelial cells.
We assessed both hotspot and rare mutant forms of PIK3CA found in bladder tumors. AKT signaling was induced in NHUC by hotspot mutants and relative potency correlated with the frequency at which these mutations are found in UC (E545K4E542K4H1047R), suggesting that cell context may provide a unique contribution to selection for specific mutations. Pathway activation was induced to a lesser degree by the rare mutants, with least activation by V136I and Q643R. This is consistent with previous studies showing that the majority of cancer-specific rare PIK3CA mutants are less potent activators of PI3K signaling than hotspot mutants. 11 --13,20 The rare mutant E545G was an exception and may be a potent oncoprotein in some UC.
Ectopic expression of hotspot PIK3CA mutant proteins led to a transient senescence-like response with increased senescenceassociated b-gal activity, increased cell volume and increased numbers of vacuolated and flattened cells. This response was greatest in cells expressing H1047R PIK3CA. As PIK3CA mutation is more common in low grade and stage UC 7 and may be an early mutational event during tumor development, this more profound oncogene-induced growth arrest induced by H1047R might prevent survival of mutant cells. Upregulation of p16 was observed in association with this effect. Deletion of chromosome 9, including CDKN2A, is common in UC and is also predicted to be an early event. Here we showed that downregulation of p16 expression reduced the senescence-like response to mutant PIK3CA in NHUC, suggesting potential co-operation between these two genetic alterations during early urothelial tumor development.
Proliferative and migratory advantages were conferred by mutant PIK3CA expression. Hotspot mutant forms, particularly E545K, increased NHUC proliferation in growth factor-depleted conditions, as reported in human mammary epithelial cells and colorectal cancer cells. 14, 21, 22 Helical domain mutant PIK3CA proteins, especially E545K, promoted growth of NHUC to higher density in both growth factor-supplemented and -depleted conditions, indicating reduced sensitivity to contact-mediated inhibition. Such an advantage in the intact urothelium in vivo could lead to clonal expansion or the development of hyperplasia. As the urothelial cells used in this study are diploid normal immortalized cells, 23 it was not expected that expression of a single oncogene would induce anchorage-independence, and this was the case. However, resistance to anoikis was apparent and was induced significantly more by E545K than H1047R.
The effects of the mutant forms in NIH3T3 cells highlighted cell context-dependent effects. Only H1047R had strong AKTactivating activity, helical domain mutants were less potent and rare UC mutants had low activity. There were also clear differences in effects on saturation density, with only H1047R having significant effect. Cell type-specific effects have been reported for some other rare PIK3CA mutants. For example, the breast cancer-associated P539R mutant expressed in chick embryo fibroblasts was less transforming than hotspot mutants, 11 but had similar transforming activity to hotspot PIK3CA mutants in the breast cell line MCF-10A. 12 Some studies have reported that mutant PIK3CA and AKT1 induce morphological transformation of NIH3T3. 13, 24 We observed no significant changes. This is consistent with our recent study that found no morphological transformation by mutant AKT1 despite stimulation of anchorage-independence. 25 Although cell context-dependent effects are important and affect relative potency in specific assays, transforming ability in NIH3T3 cells nevertheless provided useful information about oncogenicity of the rare mutant forms that could not be tested in NHUC. All mutants apart from V136I induced formation of colonies in agar. When considering the effects seen in all the experiments conducted in this study, the activity of the rare mutants can be ranked M1043I4P124L/D1017H4E545G/A1066V4Q643R4V136I. In addition to their functional effects in vitro, the rare mutants P124L and Q643R have predicted effects on p110a-p85 interaction. P124L may alter the interaction between the p85-binding domain of p110a and the iSH2 domain of p85a. This may impair the inhibitory regulation mediated by p85a. 26 --28 Q643R may interfere with the helical-C2 domain interaction within p110a and cause alterations within the PI3K heterodimer as helical and C2 domains of p110a interact with p110a-kinase domain and p85a-nSH2 domain. 15, 29 As V136I is a variant found in a cell line for which we do not have a paired constitutional DNA sample, we cannot confirm this as a somatic mutation. Taken together with the lack of induction of NIH3T3 transformation, lack of activity in assays carried out in NHUC and no predicted effect of this aminoacid change from in silico analysis of the PI3K heterodimer structure, it appears likely that this represents a rare germline polymorphism or a somatic passenger event.
Expression of mutant PIK3CA conferred a migratory advantage in NHUC. PI3K signaling is known to have a role in cell migration (reviewed in ref. 30 ) and aberrant PI3K activity correlates with cell motility and invasion in bladder 31 --34 and other epithelial cell types. 14, 35, 36 In the breast cancer cell line MDA-MB-231 modified to express either E545K or H1047R PIK3CA, 35 different effects on cell migration were reported, both inducing increased motility but only E545K PIK3CA increasing directional migration. Here, both kinase and helical domain hotspot mutant forms and all rare mutants apart from V136I and Q643R induced increased motility of NHUC, but no significant difference was noted between E542K, E545K and H1047R in directional motility assays. All three hotspot mutants induced cell movement within confluent monolayers, including movement over rather than between other cells as seen in control cell populations. This suggests that such cells may have the ability to move within the urothelium in vivo. It is not clear why we observed no differential effect of helical and kinase domain mutations on motility in NHUC. Possibly, this phenotype is not cell context --dependent, unlike the proliferation --related effects induced by helical domain mutations, which may provide a major selective advantage early in disease development.
In accord with previous findings, our study indicates that overexpression of WT PIK3CA does not induce cancer-related phenotypes in NIH3T3 or NHUC. 12, 21, 22 A small advantage was apparent both at confluence and in optimal culture conditions in NHUC, but this was minor compared with the effects of mutant forms. This is compatible with the lack of frequent PIK3CA amplification in UC.
What determines the context-dependent differential responses to these mutants? The two types of mutation have been shown to induce PI3K activation by different mechanisms. Helical domain PIK3CA mutations relieve the inhibitory effect of p85a on p110a. These mutant forms do not require p85a binding for oncogenicity but remain dependent on RAS binding. Kinase domain mutant proteins do not require RAS binding but remain dependent on p85a. 17, 37, 38 This may indicate altered dependence of kinase domain mutations on upstream growth factor signaling and could explain their reduced activity compared with helical domain mutations in growth factor-limiting conditions in normal cells.
In conclusion, we have shown that mutant PIK3CA can induce a range of phenotypic changes in NHUC, and that the potency of different mutant forms is related to their relative frequency in primary UC. Additional work is needed to identify molecular events that may co-operate with these mutations during tumor development and to test the hypothesis that kinase domain mutations are restricted in their ability to contribute to urothelial transformation in the absence of relevant co-operating upstream events. The cell models that we have developed will allow this to be explored in an isogenic setting.
MATERIALS AND METHODS

Cell culture
Telomerase-immortalized normal human urothelial cells (NHUC) 23 and mouse fibroblasts (NIH3T3) were cultured as described. 39 For NHUC growth factor-deprivation studies, cells were maintained in medium without growth factors.
Expression vectors and transduction of cell lines E542K, E545K, H1047R, P124L, V136I, E545G, Q643R, D1017H, M1043I and A1066V mutations were created by site-directed mutagenesis in PIK3CA cDNA and sequence verified. WT and mutant PIK3CA were cloned into a retroviral expression vector containing a neomycin resistance cassette (pFB Neo; Stratagene, La Jolla, CA, USA) and transfected into Phoenix A cells using siPORT XP-1 (Ambion, Huntingdon, UK). NHUC and NIH3T3 were incubated with retroviral supernatant containing 8 mg/ml polybrene and selected with 100 and 800 mg/ml G418 48 h after transduction.
p16 shRNA 40 was first sub-cloned into pGEM-U6 puro and then into pRetroSuper-puro (pRS-puro) as described. 41 p16 shRNA construct and empty vector were transduced into NHUC as above. After selection with 2 mg/ml puromycin, p16 knockdown-NHUC and control NHUC (empty vector) were transduced with E545K, H1047R and empty pFB-Neo and selected with 100 mg/ml G418.
Western blotting
Protein extraction was carried out as described 42 and protein concentration was quantified using the BIO-RAD protein assay (BIO-RAD, Hemel Hempstead, UK). SDS --PAGE and immunoblotting was carried out as described 39 and blots incubated with primary antibodies; anti-p110a, anti-pAKT (Ser473), anti-panAKT, anti-pGSK3b (Ser9), anti-GSK3b, anti-pFOXO1 (Thr24)/pFOXO3a (Thr32), anti-FOXO1, anti-FOXO3a, antipS6 (Ser235/236) and anti-S6 from Cell Signaling Technology (New England Biolabs Ltd, Hitchin, UK) and anti-p16 (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-tubulin alpha (AbD Serotec, Kidlington, Oxford, UK). Bound primary antibodies were detected using HRP-conjugated secondary antibodies and the ECL Plus kit (GE Healthcare Life Sciences, Little Chalfont, UK).
Phenotypic assays
Cell size and forward scatter analysis was performed and analyzed using the Guava EasyCyte Plus System 3 (Guava Technologies, Inc., Stamford, UK) according to the manufacturer's instructions.
b-Galactosidase (b-Gal) activity was visualized using the Senescence b-Galactosidase Staining Kit (Sigma-Aldrich Company Ltd, Poole, UK) according to the manufacturer's instructions, and total and stained cells were counted in 10 fields of view at Â 10 magnification.
For proliferation assays, 1 --3 Â 10 4 cells were plated per well in six-well dishes. Triplicate wells were counted at relevant time points using a Z2 Coulter analyzer (Beckman Coulter Ltd, High Wycombe, UK).
BrdU and p16 immunocytochemistry was performed after incubation of cells with 0.1 mM BrdU (Sigma-Aldrich Company Ltd) 24 h before fixation in paraformaldehyde. For BrdU analysis, cells were serially treated with Avidin/Biotin blocking kit (Vector Labs, Peterborough, UK), 10% normal goat serum (DAKO, Glostrup, Denmark), anti-BrdU antibody (BD Biosciences, Oxford, UK), biotin-conjugated secondary antibody (DAKO) and NovaRED substrate kit for peroxidase (Vector Labs) according to manufacturer's instructions. For p16 analysis, cells were treated with anti-p16 antibody (Autogen Bioclear, Calne, UK), alkaline phosphataseconjugated secondary antibody (DAKO), and Vector Blue Alkaline Phosphatase Substrate Kit (Vector Labs). Total and BrdU-and p16-positive cells were counted in 10 fields at Â 10 magnification.
